Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatosis 1 × cabozantinib × 30 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 14 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Osteosarcoma 3 Melanoma 3 Clear-cell metastatic renal cell carcinoma 3 Urogenital Neoplasms 2 Ureteral Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma, Ewing 2 Prostatic Neoplasms 2 Penile Neoplasms 2 Neuroendocrine Tumors 2 Kidney Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Brain Neoplasms 2 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Kaposi 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non functioning pancreatic endocrine tumor 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neoplasm Metastasis 1 Mouth Neoplasms 1

Interventions

AZD 6244 6 trametinib 1 omipalisib 1 cabozantinib 1 Waiting Lists 1 Vincristine 1 Specimen Handling 1 Magnetic Resonance Spectroscopy 1 Lasers, Solid-State 1 Lasers 1 Carboplatin 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06502171 2026-03-12

NF113

University of Alabama at Birmingham

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡